Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis

Cancer Science

Volumn 97, Issue 12, 2006, Pages 1327-1334

  Jin, Xinlian ^a,b   Yagi, Motoki ^a   Akiyama, Nagisa ^a   Hirosaki, Tomomi ^a   Higashi, Shouichi ^a   Lin, Chen Yong ^c   Dickson, Robert B ^c   Kitamura, Hitoshi ^b   Miyazaki, Kaoru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIPTASE; SERINE PROTEINASE; STROMELYSIN;

ABDOMINAL TUMOR; ANGIOGENESIS; ARTICLE; BLOOD VESSEL DIAMETER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL DENSITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH RATE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NUDE MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; SURVIVAL TIME; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE ENDOPEPTIDASES; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 33750315799     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00328.x     Document Type: Article

References (39)

1. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
2. Nelson AR, Fingleton B, Rothenberg ML. Matrisian LM. Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135-49.
3. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol 1996; 149: 273-82.
4. Wu Q. Type II transmembrane serine proteases. Curr Top Dev Biol 2003; 54: 167-206.
5. Takeuchi T, Shuman MA, Craik CS. Reverse biochemistry: Use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc Natl Acad Sci 1999; 96: 11054-61.
6. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999; 274: 18231-6.
7. Oberst M, Anders J, Xie B, Singh B et al. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301-11.
8. Oberst MD, Singh B, Ozdemirli M, Dickson RB, Johnson MD, Lin CY. Characterization of matriptase expression in normal human tissues. J Histochem Cytochem 2003; 51: 1017-25.
9. List K, Haudenschild CC, Szabo R et al. Matriptase is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21: 3765-79.
10. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-42.
11. Oberst MD, Johnson MD, Dickson RB et al. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8: 1101-7.
12. Kang JY, Dolled-Filhart M, Ocal IT et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 1101-5.
13. Jin X, Hirosaki T, Lin CY et al. Production of soluble matriptase by human cancer cell lines and cell surface activation of its zymogen by trypsin. J Cell Biochem 2005; 95: 632-47.
14. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275: 26333-42.
15. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-5.
16. Ihara S, Miyoshi E, Ko JH et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem 2002; 277: 16960-7.
17. Suzuki M, Kobayashi H, Kanayama N et al. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase. J Biol Chem 2004; 279: 14899-908.
18. Galkin AV, Mullen L, Fox WD et al. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004; 61: 228-35.
19. List K, Szabo R, Molinolo A et al. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005; 19: 1934-50.
20. Benaud C, Dickson RB, Lin CY. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur J Biochem 2001; 268: 1439-47.
21. Miyata S, Koshikawa N, Higashi S et al. Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J Biochem (Tokyo) 1999; 125: 1067-76.
22. Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. J Biol Chem 2003; 278: 26773-9.
23. Miyata S, Koshikawa N, Yasumitsu H, Miyazaki K. Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2. J Biol Chem 2000; 275: 4592-8.
24. Jin M, Udagawa K, Miyagi E et al. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001; 83: 325-33.
25. Ahmed S, Jin X, Yagi M et al. Identification of membrane-bound serine proteinase matriptase as processing enzyme of insulin-like growth factor binding protein-related protein-1 (IGFBP-rP1/angiomodulin/mac25). FEBS J 2006; 273: 615-27.
26. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
27. Seiki M, Yana I. Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003; 94: 569-74.
28. Chantrain CF, Shimada H, Jodele S et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004; 64: 1675-86.
29. Mira E, Lacalle RA, Buesa JM et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci 2004; 117: 1847-57.
30. Deryugina EI, Soroceanu L, Strongin AY. Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 2002; 62: 580-8.
31. Aimes RT, Zijlstra A, Hooper JD et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost 2003; 89: 561-72.
32. Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003; 22: 8662-70.
33. Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW, Muschel RJ. Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis 1994-95; 14: 246-58.
34. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-76.
35. Satomi S, Yamasaki Y, Tsuzuki S, Hitomi Y, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001; 287: 995-1002.
36. He CS, Wilhelm SM, Pentland AP et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-6.
37. Nagase H, Enghild JJ, Suzuki K, Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl) mercuric acetate. Biochemistry 1990; 29: 5783-9.
38. Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M. Purification and characterization of extracellular matrix-degrading metalloproteinase, matrin (pump-1), secreted from human rectal carcinoma cell line. Cancer Res 1990; 50: 7758-64.
39. Radisky DC, Levy DD, Littlepage LE et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 1999; 436: 123-7.